Skip to main content Accessibility help

Attributable Mortality of Nosocomial Acinetobacter Bacteremia

  • Mordechai Grupper (a1), Hanna Sprecher (a2), Tania Mashiach (a1) and Renato Finkelstein (a1) (a3)



To determine the attributable mortality and outcome of nosocomial Acinetobacter bacteremia.


Matched, retrospective cohort study.


Large, university-based, tertiary care center.


Of 219 patients with nosocomial Acinetobacter bacteremia identified by prospective surveillance during a 3-year period, 52 met the criteria for the study and were matched to a control patient by age, sex, primary and secondary diagnosis, operative procedures, and date of admission.


A 100% success rate was achieved in the proportion of case patients and control patients matched for the compared criteria, except for major operative procedures (88%) and the presence of an important secondary underlying disease (54.5%). Twenty-nine (55.7%) of the case patients died, compared with 10 (19.2%) of the control patients (P < .001). The attributable mortality was 36.5% (95% CI, 27%-46%) and the risk ratio for death was 2.9 (95% CI, 1.58-5.32). In a multivariate survival analysis, older age, mechanical ventilation, renal failure, and Acinetobacter bacteremia (hazard ratio [HR], 4.41; 95% confidence interval [CI], 1.97-9.87; P < .001) were found to be independent predictors of mortality. There was a trend for a longer median duration of hospitalization among case patients, compared with control patients (11.5 vs. 6.5 days; P = .06). Three isolates were resistant to all but 1 antibiotic tested (colistin), and 45 isolates (86.5%) were resistant to 4 or more different antibiotic classes.


When adjusted for risk-exposure time and severity of disease at admission, nosocomial Acinetobacter bacteremia is associated with mortality in excess of that caused by the underlying diseases alone.


Corresponding author

Infectious Diseases Unit, Rambam Medical Center, 31096—Bat Galim, Haifa, Israel (


Hide All
1.Urban, C, Segal-Maurer, S, Rahal, J. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:12681274.
2.Bergogne-Berezin, E, Towner, KL. Acinetobacter spp. as nosocomial pathogens: microbiologic, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148165.
3.Garmendia, JLG, Leyba, OC, Montero, JG, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001;33:939946.
4.Allen, DM, Hartman, BJ. Acinetobacter species. In: Mandell, G, Bennett, J, Dolin, R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier, 2005:26322636.
5.Siau, H, Yuen, KY, Ho, PL, Wong, SS, Woo, PCY. Acinetobacter bacteremia in Hong Kong: prospective study and review. Clin Infect Dis 1999;28:2630.
6.Wisplinghoff, H, Edmond, MB, Pfaller, MA, Jones, RN, Wenzel, RP, Seifert, H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31:6907.
7.Seifert, H, Strate, A, Pulverer, G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995;74:340349.
8.Jerassy, Z, Yinnon, AM, Mazouz-Cohen, S, et al. Prospective hospital-wide studies of 505 patients with nosocomial bacteremia in 1997 and 2002. J Hosp Infect 2006;62:230236.
9.Wisplinghoff, H, Perbix, W, Seifert, H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28:5966.
10.Blot, S, Vandewoude, K, Colardyn, F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003;29:4715.
11.McCabe, WR, Jackson, GG. Gram negative bacteremia: I. etiology and ecology. Arch Intern Med 1962;110:845855.
12.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing. Disk Diffusion Supplemental Table. Approved standard M100-S10 (M2). Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
13.Freid, VM, Prager, K, MacKay, AP, Xia, H. Health, United States, 2003. Hyattsville, Maryland: National Center for Health Statistics, 2003.
14.Vallès, J, León, C, Alvarez-Lerma, F, for the Spanish Collaborative Group of Infections in Intensive Care Unit of SEMIUC. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997;24:387395.
15.Pittet, D, Tarara, D, Wenzel, RP. Nosocomial bloodstream infections in critically ill patients: excess length of stay, extra cost, and attributable mortality. JAMA 1994;271:15981601.
16.Wisplinghoff, H, Bischoff, T, Tallent, SM, Seifert, H, Wenzel, RP, Edmont, MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309317.
17.Cisneros, JM, Reyes, MJ, Pachon, J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:10261032.
18.Martin, MA, Pfaller, MA, Wenzel, RP. Coagulase-negative staphylococcal bacteremia, mortality and hospital stay. Ann Intern Med 1989;110:916.
19.Senol, E, Desjardin, J, Stark, PC, Barefoot, SL, Snydman, DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002;34:16531656.
20.Gudlaugsson, O, Gillespie, S, Lee, K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:11721177.
21.Girou, E, Stephan, F, Novara, A, Safar, M, Fagon, JY. Risk factors and outcome of nosocomial infections: results of matched case-control study of ICU patients. Am J Resp Crit Care Med 1998;157:11511158
22.Soufir, L, Timsit, JF, Mahe, C, Carlet, J, Regnier, B, Chevret, S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999;20:396401.
23.Seifert, H, Baginski, R, Schulze, A, Pulverer, G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993;37:750753.
24.Montero, A, Ariza, J, Corbella, X, et al. Efficacy of Colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:19461952.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed